Refractory celiac disease.
Study Goal
The researchers aimed to review the clinical and pathologic features of refractory celiac disease (RCD) and explore recent pathogenic findings in RCDII, particularly its link to T-cell lymphomagenesis.
Results Summary
The study found that a subset of celiac disease patients becomes refractory to a gluten-free diet, leading to persistent symptoms and intestinal damage. RCDII, a severe form, is identified as a low-grade intraepithelial lymphoma with poor prognosis.
Population
Patients with celiac disease who develop refractory symptoms despite a gluten-free diet.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
gluten-free diet | no change | symptoms of malabsorption and intestinal villous atrophy | small subset of patients with celiac disease | - | become refractory to | #1 |
- | neutral | type II RCD (RCDII) | - | - | has a poor prognosis | #2 |
A small subset of patients with celiac disease become refractory to a gluten-free diet, with persistent or recurrent symptoms of malabsorption and intestinal villous atrophy. This condition, defined as refractory celiac disease (RCD), is diagnosed after other small bowel diseases with villous atrophy are excluded. RCD is subdivided into 2 subgroups: type I RCD and type II RCD (RCDII). This latter condition is considered a low-grade intraepithelial lymphoma and has a poor prognosis. This article reviews the clinical and pathologic features of RCD and recent pathogenic findings in RCDII, offering a model to study how inflammation can drive T-cell lymphomagenesis.